drugset / Trial / NCT06789757

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

NCT06789757

Phase 2 Recruiting 19 enrolled Inova Health Care Services
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.

Timeline

Start
2025-02-25
Primary completion
2026-10-27
Completion
2028-01-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 5 mg
Background Atezolizumab Monoclonal antibody 1200 mg
Background Bevacizumab Monoclonal antibody 15 mg/kg